Pharnext SCA
OTC:PNEXF

Watchlist Manager
Pharnext SCA Logo
Pharnext SCA
OTC:PNEXF
Watchlist
Price: 999 999.9999 USD Market Closed
Market Cap: 6T USD
Have any thoughts about
Pharnext SCA?
Write Note

Pharnext SCA
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pharnext SCA
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Pharnext SCA
OTC:PNEXF
Additional Paid In Capital
€15.1m
CAGR 3-Years
-49%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Additional Paid In Capital
€593.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Additional Paid In Capital
€386m
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
8%
G
Genfit SA
PAR:GNFT
Additional Paid In Capital
€446.5m
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
17%
Inventiva SA
PAR:IVA
Additional Paid In Capital
€201.9m
CAGR 3-Years
13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Additional Paid In Capital
€33.6m
CAGR 3-Years
-6%
CAGR 5-Years
-26%
CAGR 10-Years
-12%
No Stocks Found

Pharnext SCA
Glance View

Market Cap
6T USD
Industry
Biotechnology

Pharnext SCA, a biopharmaceutical innovator, stands as a pioneer in the world of "pleotherapy," a unique approach that repurposes existing drugs to simultaneously target multiple disease pathways. Founded in 2007 by renowned scientists, the company has developed a proprietary drug discovery platform known as PLEOTHERAPY™. This platform ingeniously combines network pharmacology with advanced algorithms, allowing Pharnext to identify optimal combinations of existing molecules. Such combinations, termed "pleodrugs," are designed to tackle complex neurological diseases for which there are currently few effective treatments. By leveraging already approved compounds, Pharnext significantly streamlines the path to clinical development, reducing both time and cost—a critical advantage in the pharmaceutical sector. Monetary gains for Pharnext primarily arise from developing and partnering these novel pleodrugs. By focusing on rare neurological conditions, such as Charcot-Marie-Tooth disease type 1A (CMT1A), Pharnext positions itself in niche markets with unmet medical needs and limited competition. Their lead candidate, PXT3003 for CMT1A, exemplifies this strategy, promising a new therapeutic avenue for patients while potentially establishing a new revenue stream upon commercialization. Moreover, Pharnext often collaborates with other pharmaceutical firms to both share the financial burden of drug development and enhance market penetration, thus diversifying and amplifying its income sources. Through its innovative model and strategic partnerships, Pharnext seeks to carve out a distinct and profitable niche within the biopharmaceutical landscape.

PNEXF Intrinsic Value
Not Available

See Also

What is Pharnext SCA's Additional Paid In Capital?
Additional Paid In Capital
15.1m EUR

Based on the financial report for Jun 30, 2023, Pharnext SCA's Additional Paid In Capital amounts to 15.1m EUR.

What is Pharnext SCA's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
-23%

Over the last year, the Additional Paid In Capital growth was 6%. The average annual Additional Paid In Capital growth rates for Pharnext SCA have been -49% over the past three years , -23% over the past five years .

Back to Top